Brookline Capital Management Predicts SCYNEXIS Q4 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Investment analysts at Brookline Capital Management lifted their Q4 2025 earnings per share (EPS) estimates for shares of SCYNEXIS in a note issued to investors on Thursday, November 6th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of $0.29 per share for the quarter, up from their previous forecast of $0.23.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. SCYNEXIS had a negative return on equity of 43.04% and a negative net margin of 599.05%.The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.15 million.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of SCYNEXIS to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a research note on Wednesday, November 5th. Finally, Guggenheim decreased their target price on SCYNEXIS from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

SCYNEXIS Stock Up 0.2%

Shares of NASDAQ:SCYX opened at $0.60 on Monday. SCYNEXIS has a fifty-two week low of $0.58 and a fifty-two week high of $1.49. The firm’s 50 day moving average price is $0.85 and its 200 day moving average price is $0.82. The stock has a market cap of $25.22 million, a price-to-earnings ratio of -1.50 and a beta of 1.69.

Institutional Investors Weigh In On SCYNEXIS

Several hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in shares of SCYNEXIS during the second quarter worth about $27,000. Sequoia Financial Advisors LLC purchased a new position in shares of SCYNEXIS in the 3rd quarter valued at approximately $41,000. GSA Capital Partners LLP increased its holdings in shares of SCYNEXIS by 95.2% in the third quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock valued at $80,000 after purchasing an additional 50,916 shares during the period. Tabor Asset Management LP acquired a new position in shares of SCYNEXIS in the first quarter valued at approximately $181,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of SCYNEXIS by 4.2% during the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after purchasing an additional 14,689 shares during the last quarter. Institutional investors and hedge funds own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.